


METAFORA BIOSYSTEMS BRINGS TO MARKET ITS FIRST BIOMARKER FOR CELL METABOLISM

Évry (France), May 26th, 2014

METAFORA biosystems, a Genopole-accredited company, announced the market launch of its unique cell metabolism biomarker, **Glut1.RBD**. This new tool intended for biomedical research offers a wide range of uses, from drug discovery and development to disease research, particularly in blood pathologies.

METAFORA biosystems develops innovative biomarkers based on receptor binding domains, or RBDs, which are ligands to specific cellular nutrient transporters. These biomarkers are meant for preclinical and clinical research, where, among other things, they can be used to evaluate the efficacy or toxicity of therapeutic molecules or to assess the functional potential of stem cells before their use in regenerative medicine.



METAFORA biosystems has begun marketing **Glut1.RBD**, a novel biomarker capable of identifying the cell membrane's major glucose transporter, called **Glut1**. **Glut1.RBD** allows for the quantification of this key element of cellular metabolism, and thus reveals the energy imbalances that accompany disease, toxic processes, etc. **Glut1.RBD** is designed for easy and rapid use in several classic cell analysis techniques.

Beyond **Glut1**, METAFORA biosystems is also developing innovative markers for other nutrient transporters with the goals of enabling the meticulous exploration of cellular metabolism and accompanying the development of new drugs. Other kits will be brought to the market before year-end 2014. *"With our new product **Glut1.RBD**, the first of a series of 6 kits for the preclinical research market, researchers in pharmaceuticals, cosmetics or other fields will be able to demonstrate, for example, energy stress as we did in a recent publication (Li et al., J Biomol Screen, May 2014)"*, explains Luc d'Auriol, President of METAFORA biosystems. *"Our technology is rapid, easy to use, and sharply focused on the identification and development of biomarkers that provide a signature of the adaptation of a cell to its environment."*

Contact METAFORA biosystems: Luc d'Auriol or Vincent Petit – contact@metafora-biosystems.com – +33 (0)1 60 87 89 25

Genopole press contact: Véronique Le Boulc'h – veronique.leboulch@genopole.fr – +33 (0)1 60 87 44 98

About METAFORA biosystems. METAFORA biosystems was founded in 2011 and incubated **first in Montpellier then at** Genopole in Évry, France. The company is focused on diagnostics and develops metabolic biomarkers based on a proprietary set of proteins specific to nutrient transporters. These tools enable the generation of signatures of the cell's metabolic state, be it in normal conditions or when it is disturbed, for example by disease or medication. METAFORA biosystems develops its METAscreen® technology as kits, for use in research currently and in clinical diagnostics (personalized medicine) in the near future.

www.metafora-biosystems.com

About Genopole. Genopole is the leading French biopark dedicated to research in genetics and biotechnologies for healthcare and the environment. Genopole unites 19 research laboratories, 80 biotech companies and 21 technical platforms as well as university training programs (Évry-Val-d'Essonne University). Its objectives are to favor the development of research in genomics, post-genomics and other related fields, assure the transfer of resulting technology to the industrial sector, establish academic-level training programs for these fields, and finally to create and support biotech companies. Genopole is funded mainly by the Ile-de-France Regional Council (30%), the Essonne Department Council (26.5%) and the French State (15.7%).

www.genopole.fr